Achim Sauer

Dr. Achim Sauer

Boerhinger Ingelheim Pharma GmbH & Co. KG
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CBClemens Braun
Clemens Braun
ASAtsushi Sakamoto
Atsushi Sakamoto
HFHolger Fuchs
Holger Fuchs
NINaoki Ishiguro
Naoki Ishiguro
SSShinobu Suzuki
Shinobu Suzuki
ASAchim Sauer
Achim Sauer

27 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YCYunhai Cui
Yunhai Cui
CDCyril Desevaux
Cyril Desevaux
ITInes Truebenbach
Ines Truebenbach
PSPeter Sieger
Peter Sieger
KKKlaus Klinder
Klaus Klinder
ASAchim Sauer
Achim Sauer
Bidirectional permeability measurement with cellular models grown on Transwell inserts is widely used in pharmaceutical research since it not only provides information about the passive permeability of a drug, but also about transport proteins involved in the active transport of drug substances across physiological barriers. With the increasing number of investigative drugs coming from chemical space beyond Lipinski’s Rule of 5, it becomes more and more challenging to provide meaningful data with the standard permeability assay. This is exemplified here by the difficulties we encountered with the cyclic depsipeptides emodepside and its close analogs with molecular weight beyond 1000 daltons and cLogP beyond 5. The aim of this study is to identify potential reasons for these challenges and modify the permeability assays accordingly. With the modified assay, intrinsic permeability and in vitro efflux of depsipeptides could be measured reliably. The improved correlation to in vivo bioavailability and tissue distribution data indicated the usefulness of the modified permeability assay for the in vitro screening of compounds beyond the Rule of 5.

17 February 2021 in Molecular Pharmaceutics
Verified
Journal Article
Open access
AHAnam Hammid
Anam Hammid
JFJohn Fallon
John Fallon
TLToni Lassila
Toni Lassila
GSGiulia Salluce
Giulia Salluce
PSPhilip C. Smith
Philip C. Smith
PHPaavo Honkakoski
Paavo Honkakoski
Hydrolytic reactions constitute an important pathway of drug metabolism and a significant route of prodrug activation. Many ophthalmic drugs and prodrugs contain ester groups that greatly enhance their permeation across several hydrophobic barriers in the eye before the drugs are either metabolized or released, respectively, via hydrolysis. Thus, the development of ophthalmic drug therapy requires the thorough profiling of substrate specificities, activities, and expression levels of ocular esterases. However, such information is scant in the literature, especially for preclinical species often used in ophthalmology such as rabbits and pigs. Therefore, our aim was to generate systematic information on the activity and expression of carboxylesterases (CESs) and arylacetamide deacetylase (AADAC) in seven ocular tissue homogenates from these two species. The hydrolytic activities were measured using a generic esterase substrate (4-nitrophenyl acetate) and, in the absence of validated substrates for rabbit and pig enzymes, with selective substrates established for human CES1, CES2, and AADAC (d-luciferin methyl ester, fluorescein diacetate, procaine, and phenacetin). Kinetics and inhibition studies were conducted using these substrates and, again due to a lack of validated rabbit and pig CES inhibitors, with known inhibitors for the human enzymes. Protein expression levels were measured using quantitative targeted proteomics. Rabbit ocular tissues showed significant variability in the expression of CES1 (higher in cornea, lower in conjunctiva) and CES2 (higher in conjunctiva, lower in cornea) and a poor correlation of CES expression with hydrolytic activities. In contrast, pig tissues appear to express only CES1, and CES3 and AADAC seem to be either low or absent, respectively, in both species. The current study revealed remarkable species and tissue differences in ocular hydrolytic enzymes that can be taken into account in the design of esterase-dependent prodrugs and drug conjugates, the evaluation of ocular effects of systemic drugs, and in translational and toxicity studies.

2 October 2018 in Adipocyte
Verified
Journal Article
Open access
TBTamara Baader-Pagler
Tamara Baader-Pagler
MEMatthias Eckhardt
Matthias Eckhardt
FHFrank Himmelsbach
Frank Himmelsbach
ASAchim Sauer
Achim Sauer
BSBirgit E. Stierstorfer
Birgit E. Stierstorfer
BHBradford S. Hamilton
Bradford S. Hamilton
Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.

3 September 2023 in Drug Discovery Today
Verified
Journal Article
Closed access
CTChristofer S Tautermann
Christofer S Tautermann
JBJens Markus Borghardt
Jens Markus Borghardt
RPRoland Pfau
Roland Pfau
MZMatthias Zentgraf
Matthias Zentgraf
NWNils Weskamp
Nils Weskamp
ASAchim Sauer
Achim Sauer

11 November 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YCYunhai Cui
Yunhai Cui
RLRalf Lotz
Ralf Lotz
HRHermann Rapp
Hermann Rapp
KKKlaus Klinder
Klaus Klinder
AHAnneke Himstedt
Anneke Himstedt
ASAchim Sauer
Achim Sauer
Movement of xenobiotic substances across the blood–brain barrier (BBB) is tightly regulated by various transporter proteins, especially the efflux transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Avoiding drug efflux at the BBB is a unique challenge for the development of new central nervous system (CNS) drugs. Drug efflux at the BBB is described by the partition coefficient of unbound drug between brain and plasma (Kp,uu,brain) which is typically obtained from in vivo and often additionally in vitro measurements. Here, we describe a new method for the rapid estimation of the in vivo drug efflux at the BBB of rats: the measurement of the partition coefficient of a drug between brain and skeletal muscle (Kp,brain/muscle). Assuming a closely similar distribution of drugs into the brain and muscle and that the efflux transporters are only expressed in the brain, Kp,brain/muscle, similar to Kp,uu,brain, reflects the efflux at the BBB. The new method requires a single in vivo experiment. For 64 compounds from different research programs, we show the comparability to other approaches used to obtain Kp,uu,brain. P-gp- and BCRP-overexpressing cell systems are valuable in vitro tools for prescreening. Drug efflux at the BBB can be most accurately predicted based on a simple algorithm incorporating data from both in vitro assays. In conclusion, the combined use of our new in vivo method and the in vitro tools allows an efficient screening method in drug discovery with respect to efflux at the BBB.